Gilead Sciences (WBO:GILD) Buyback Yield % : 0.94 (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Gilead Sciences's current buyback yield was 0.94%.

Gilead Sciences Buyback Yield % Historical Data

The historical data trend for Gilead Sciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Buyback Yield % Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

1.86

1.88

0.41

1.04

0.77

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buyback Yield %	Get a 7-Day Free Trial															2.35	1.20	0.52	0.91	0.50

Competitive Comparison of Gilead Sciences's Buyback Yield %

For the Drug Manufacturers - General subindustry, Gilead Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Buyback Yield % falls into.

Gilead Sciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Gilead Sciences's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-917	+	212.744)	/	91534.0984
	=	0.77%

Gilead Sciences's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (-137.55	+	23.842)	*	4	/	91534.0984
	=	0.50%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.

Gilead Sciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (WBO:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.